close read more

Our 5 therapeutic areas

To discover new treatments that improve patients’ lives, Servier invests an average of 25% of
its sales revenue (excl. generic medicines) in R&D. The Group focuses its research and development
efforts in therapeutic areas where needs are substantial.

    Immune-inflammatory diseases

    10%

    of cases are severe
    and do not respond to any treatment

    30.000

    patients with systemic scleroderma in Europe

    189.000

    patients with Sjögren’s disease,
    the 2nd most common autoimmune disease

    Immune-inflammatory diseases are characterized by an inadequate response to the immune system that turns against the patient’s own tissues.

    Servier concentrates its research and development efforts on three autoimmune diseases with very high medical needs: systemic lupus erythematosus, scleroderma and Sjögren’s syndrome.

    Servier relies on several partnerships, for example with OSE Immunotherapeutics on Sjögren disease and since 2018, with ImmunoQure AG for the development of anti-interferon alpha antibodies in lupus. The year was also marked by the end of the patients’ enrollment in the global clinical study ROCCELLA (phase II) conducted in collaboration with Galapagos for the treatment of knee osteoarthritis.